A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer

Oncology

Volumn 66, Issue 5, 2004, Pages 371-378

  Rosati, Gerardo ^a,f   Tucci, Aniello ^b   Rinaldi, Antonio ^c   Colarusso, Diodoro ^d   Pizza, Carmine ^b   Reggiardo, Giorgio ^e   Manzione, Luigi ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Civil Hospital of Nola   (Italy)

^c Medical Oncology Unit   (Italy)

^d Civil Hospital of Lagonegro   (Italy)

^e Medi Service   (Italy)

^f NONE   (Italy)

Author keywords

5 Fluorouracil; Alternating regimen; Irinotecan; Leucovorin; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSESTHESIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND AND FOOT SYNDROME; HEALTH STATUS; HUMAN; INCIDENCE; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHEMATOLOGICAL TOXICITY; PARESTHESIA; PATIENT ATTITUDE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; SYNDROME; THROMBOCYTOPENIA; TOXICITY; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; STOMATITIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 4444371506     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079485     Document Type: Article

References (30)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring JL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Minet JL, Levi F: Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
5. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:129a.
6. Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP: N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 2003;22:252.
7. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet 2000;356:373-378.
8. Rosati G, Rossi A, Reggiardo G, Manzione L: A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. Oncology 2002;62:209-215.
9. Bulusu VR: Irinotecan and 5-fluorouracil in colorectal cancer: Time for a pause? Eur J Cancer 1998;34:286-289.
10. Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001;19:3456-3462.
11. Rosati G, Rossi A, Tucci A, Pizza C, Manzione L: Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol 2001;12:669-674.
12. Miller AB, Hoogstraten B, Staquet N: Reporting results of cancer treatment. Cancer 1981;47:207-214.
13. Simon R: Optimal two stage design for phase II clinical trials. Control Clin Trial 1989;10:1-10.
14. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-458.
15. Maindrault F, Louvet C, André T, Gilles V, Artru P, Tournigand C, Garcia M, Gervais H, Carola E, Krulik M, de Gramont A: Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR). Proc Am Soc Clin Oncol 2001;20:146a.
16. Tournigand C, Louvet C, Quinaux E, André T, Lledo G, Flesch M, Ganem G, Landi B, Colin P, Denet C, Mery-Mignard D, Risse M, Buyse M, de Gramont A: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:124a.
17. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M; Oncology Multidisciplinary Research Group (GERCOR): High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 2001;37:1000-1005.
18. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
19. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20:3478-3483.
20. Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G: Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: A Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol 2000;11:163-167.
21. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
22. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Thopam CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
23. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
24. Aschele A, Lonardi S, Sartor L, Perin A, Koussis B, Nicoletto O, Monfardini S: A phase II study of leucovorin (LV)-modulated continuous infusion (CI) fluorouracil (FU) + CPT-11 alternating with LV-modulated CI FU + oxaliplatin (L-OHP) in advanced colorectal cancer (CCR): High activity and low toxicity. Eur J Cancer 2001;37(suppl 6):S309.
25. Bécouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, Provençal J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001;19:4195-4201.
26. Souglakos J, Mavroudis D, Kakolyris S, Kourousis C, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002;20:2651-2657.
27. Comella P, Casaretti R, De Rosa V, Avallone A, Izzo F, Fiore F, Lapenta L, Comella G: Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: A dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 2002;13:1874-1881.
28. Calvo E, Cortés J, González-Cao M, Rodriguez J, Aramendia JM, Fernandez-Hidalgo O, Martin-Algarra S, Salgado JE, Martinez-Monge R, de Irala J, Brugarolas A: Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. Oncology 2002;63:254-265.
29. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte F: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:4006-4014.
30. Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, Kramar A: An open phase I study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14:481-489.